
Kofi Clarke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/936080/publications.pdf Version: 2024-02-01



KOEL CLARKE

#	Article	IF	CITATIONS
1	Referral for Dietary Intervention in Celiac Disease Is Low among Gastroenterologists and Primary Care Providers. Digestive Diseases, 2023, 41, 343-352.	1.9	1
2	COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2022, , 1.	2.3	9
3	Post-polypectomy follow-up recommendations by practicing academic gastroenterologists—does number of years in practice matter?. International Journal of Colorectal Disease, 2022, 37, 979-982.	2.2	0
4	Symptoms associated with healthcare resource utilization in the setting of inflammatory bowel disease. Scientific Reports, 2022, 12, .	3.3	6
5	Impact of COVID-19 Pandemic on Training: Global Perceptions of Gastroenterology and Hepatology Fellows in the USA. Digestive Diseases and Sciences, 2021, 66, 3307-3311.	2.3	20
6	Abdominal pain in quiescent inflammatory bowel disease. International Journal of Colorectal Disease, 2021, 36, 93-102.	2.2	10
7	Addressing Fecal Incontinence in Inflammatory Bowel Disease Patients: A Messy Problem. Crohn's & Colitis 360, 2021, 3, .	1.1	0
8	Symptoms and Extraintestinal Manifestations in Active Cannabis Users with Inflammatory Bowel Disease. Cannabis and Cannabinoid Research, 2021, , .	2.9	2
9	Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?. Crohn's & Colitis 360, 2021, 3, .	1.1	3
10	Redeploying gastroenterologists during the COVID-19 pandemic: early experience with telehealth including clinical access and financial implications. Gastroenterology Report, 2021, 9, 276-278.	1.3	1
11	Targeted Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease: Is That the Best Way Forward?. Crohn's & Colitis 360, 2021, 3, .	1.1	0
12	Initial endoscopic intervention is not associated with reduced risk of recurrent gastrointestinal bleeding in left ventricular assist device patients. Annals of Gastroenterology, 2021, 34, 660-668.	0.6	0
13	Impact of a nurse navigator on a dedicated inflammatory bowel disease-focused gastroenterology clinic. Annals of Gastroenterology, 2021, 34, 675-679.	0.6	1
14	Polysubstance Use in Inflammatory Bowel Disease. Journal of Digestive Diseases, 2021, , .	1.5	4
15	Indeterminate Colitis – Update on Treatment Options. Journal of Inflammation Research, 2021, Volume 14, 6383-6395.	3.5	8
16	Mantle Cell Lymphoma and Ampullary Tubulovillous Adenoma in Celiac Disease. Clinical Gastroenterology and Hepatology, 2020, 18, e144.	4.4	0
17	<p>Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy</p> . Clinical and Experimental Gastroenterology, 2020, Volume 13, 339-350.	2.3	30
18	Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes. Crohn's & Colitis 360, 2020, 2, .	1.1	0

KOFI CLARKE

#	Article	IF	CITATIONS
19	Abdominal Pain and Anxious or Depressed State Are Independently Associated With Weight Loss in Inflammatory Bowel Disease. Crohn's & Colitis 360, 2020, 2, otaa047.	1.1	1
20	Dysplasia detection is similar between chromoendoscopy and high-definition white-light colonoscopy in inflammatory bowel disease patients: a US-matched case-control study. International Journal of Colorectal Disease, 2020, 35, 2301-2307.	2.2	10
21	Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study. Gastroenterology, 2020, 159, 1575-1578.e4.	1.3	104
22	Allergic and Immunologic Perspectives of Inflammatory Bowel Disease. Clinical Reviews in Allergy and Immunology, 2019, 57, 179-193.	6.5	28
23	A Comprehensive Review of Celiac Disease/Gluten-Sensitive Enteropathies. Clinical Reviews in Allergy and Immunology, 2019, 57, 226-243.	6.5	56
24	Increased Risk of Influenza and Influenza-Related Complications Among 140,480 Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 369-376.	1.9	117
25	Gastrointestinal hypoalgesia in inflammatory bowel disease. Annals of Gastroenterology, 2019, 33, 45-52.	0.6	4
26	Variations in the medical treatment of inflammatory bowel disease among gastroenterologists. Gastroenterology Report, 2018, 6, 61-64.	1.3	12
27	Case of colonic mucosal Schwann cell hamartoma and review of literature on unusual colonic polyps. BMJ Case Reports, 2018, 2018, bcr-2018-224931.	0.5	5
28	An Endoscopic Double Take. Gastroenterology, 2018, 155, 1315-1316.	1.3	1
29	Influences and Impact of Anxiety and Depression in the Setting of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2303-2308.	1.9	96
30	Neoterminal Ileal Polyposis and Ulceration after Restorative Proctocolectomy with a Current Review of the Literature. Case Reports in Gastroenterology, 2018, 12, 158-164.	0.6	0
31	Su1815 - Characterization of the Silent IBD Patient. Gastroenterology, 2018, 154, S-594.	1.3	0
32	Sa1833 - Abdominal Pain in Inflammatory Bowel Disease Impacts Dietary Habits Independently of Inflammation. Gastroenterology, 2018, 154, S-413.	1.3	2
33	College inflammatory bowel disease (C-IBD) day: a targeted approach to shared decision-making in college age students with IBD—a 2-year pilot project. International Journal of Colorectal Disease, 2017, 32, 1019-1023.	2.2	0
34	Causes and Consequences of Affective Spectrum Disorders in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S795.	1.3	0
35	Abdominal Pain Modifiers in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S779.	1.3	0
36	Affective Spectrum Disorders Significantly Influence Total Symptom Burden in Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S794.	1.3	1

KOFI CLARKE

#	Article	IF	CITATIONS
37	Increased Health Care Resource Utilization in Inflammatory Bowel Disease Associated with Affective Spectrum Disorders. Gastroenterology, 2017, 152, S796.	1.3	0
38	Effect of clinical and laboratory parameters on quality of life in celiac patients using celiac disease-specific quality of life scores. Scandinavian Journal of Gastroenterology, 2017, 52, 1235-1239.	1.5	4
39	Febrile Neutropenia with Thrombocytopenia after Infliximab Induction in a Patient with Ulcerative Colitis. Case Reports in Gastroenterology, 2017, 10, 596-599.	0.6	3
40	Diagnostic yield from colon biopsies in patients with inflammatory bowel disease and suspected cytomegalovirus infection: is it worth it?. Annals of Gastroenterology, 2017, 30, 429-432.	0.6	3
41	IBD LIVE Case Series–Case 4. Inflammatory Bowel Diseases, 2016, 22, 1462-1472.	1.9	1
42	Endoscopic Pitfalls: Adult Unrepaired Cleft Palate. American Journal of Gastroenterology, 2016, 111, 27.	0.4	0
43	Immunoglobulin G4 (IgG4)-associated pouchitis – Part of IgG4 related disease? A case series and review of the literature. Digestive and Liver Disease, 2016, 48, 817-819.	0.9	4
44	731 Recognition of Endoscopic Stigmata of Acute Gastrointestinal Bleeding: Is It in the Eye of the Beholder?. Gastroenterology, 2016, 150, S148.	1.3	0
45	Sa1403 Clinical Parameters and Quality of Life in Patients With Celiac Disease Using CD-QOL Scores (Celiac Disease-Specific Assessment Instrument for Quality of Life). Gastroenterology, 2016, 150, S306.	1.3	0
46	Endoscopic Stigmata: Recognition Lies in the Eye of the Beholder?. Gastroenterology, 2016, 151, 203-204.	1.3	0
47	Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists. Annals of Gastroenterology, 2016, 30, 192-196.	0.6	7
48	Rare case of entero-enteric intussusception caused by small bowel metastasis from a cardiac liposarcoma. World Journal of Gastrointestinal Oncology, 2016, 8, 326.	2.0	6
49	An Isolated Colonic Neurofibroma. Annals of Gastroenterology, 2016, 29, 381.	0.6	4
50	Sa1742 Pre-Pylorus Pseudomelanosis - "lt Can Happen― Gastroenterology, 2015, 148, S-319-S-320.	1.3	0
51	Pre-pyloric pseudomelanosis. Digestive and Liver Disease, 2015, 47, 617.	0.9	1
52	Mo1096 Bridges to Excellence (BTE) Quality Indicators in Inflammatory Bowel Disease (IBD) - Variance in Utilization Between IBD Specialists and Non-IBD Gastroenterologists. Gastroenterology, 2015, 148, S-605.	1.3	0
53	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma—challenges in management. International Journal of Colorectal Disease, 2015, 30, 1595-1602.	2.2	5
54	Ultra-high C-reactive protein levels in hospitalized inflammatory bowel disease (IBD) patients predicts serious complications. International Journal of Colorectal Disease, 2014, 29, 133-133.	2.2	0

KOFI CLARKE

#	ARTICLE	IF	CITATIONS
55	Management of ulcerative colitis pre- and post-liver transplant for primary sclerosing cholangitis: two case reports and review of literature. International Journal of Colorectal Disease, 2014, 29, 1313-1320.	2.2	3
56	Su1306 Protease Activity Analysis and Pathologic Examination on the Same Endoscopic Biopsy Specimen in Inflammatory Bowel Disease. Gastroenterology, 2014, 146, S-432.	1.3	0
57	Managing risks of TNF inhibitors: An update for the internist. Cleveland Clinic Journal of Medicine, 2014, 81, 115-127.	1.3	3
58	Recurrent Blood Eosinophilia in Ulcerative Colitis Is Associated with Severe Disease and Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2013, 58, 222-228.	2.3	34
59	Pseudomelanosis duodeni in a postrenal transplant patient. BMJ Case Reports, 2013, 2013, bcr2013200466-bcr2013200466.	0.5	4
60	Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflammatory Bowel Diseases, 2012, 18, 174-179.	1.9	46
61	Methicillin-resistant Staphylococcus aureus (MRSA) colitis—is there a problem?. International Journal of Colorectal Disease, 2012, 27, 417-418.	2.2	5
62	What is Causing the Increase in Incidence of Acute Pancreatitis (AP)?. Gastroenterology, 2011, 140, S-384.	1.3	1
63	Endoscopic Evidence of Active Inflammation Does Not Lead Physicians to Make Medication Adjustments in Ulcerative Colitis (UC) Patients. Gastroenterology, 2011, 140, S-423.	1.3	1
64	Gastrointestinal and Hepatic Involvement in Sarcoidosis: A Biopsy Proven Cohort. Gastroenterology, 2011, 140, S-727.	1.3	2
65	Unique abscess in ulcerative colitis. International Journal of Colorectal Disease, 2011, 26, 1217-1218.	2.2	0
66	Response Friedman and Sparrow re: Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2011 [Epub ahead of print] Inflammatory Bowel Diseases, 2011, 17, E163.	1.9	1
67	Screening and Treatment of Glucocorticoid-Induced Osteoporosis in Rheumatoid Arthritis Patients in an Urban Multispecialty Practice. Journal of Clinical Rheumatology, 2009, 15, 61-64.	0.9	13
68	RDW as an Additional Marker in Inflammatory Bowel Disease/Undifferentiated Colitis. Digestive Diseases and Sciences, 2008, 53, 2521-2523.	2.3	59
69	Centralising curriculum feedback from graduates of small programmes. Medical Education, 2005, 39, 1164-1165.	2.1	О